Melbourne-Based Biota Closed US$102 Million License with Boehringer Ingelheim for Hepatitis C Virus (HCV) Program
A leading Australian antiviral drug development company - Biota Holdings Limited (ASX: BTA) - have entered into a worldwide research collaboration and licensing agreement with Boehringer Ingelheim (10922165) for the development and commercialization of Biota's novel nucleoside analogues designed to treat Hepatitis C Virus (HCV) infections and potentially other diseases.
The terms of the said agreement includes:
- Biota is eligible to receive payments up to US$102 million based on products achieving certain clinical, regulatory and commercialization milestones, including an initial technology access fee and research support.
- Biota would receive royalties on future sales of licensed products marketed by Boehringer Ingelheim.
- Biota is responsible for drug discovery research and Boehringer Ingelheim is responsible for worldwide development of potential compounds and their commercialization.
- Biota and Boehringer Ingelheim will be equally represented on the Joint Research Committee to oversee and coordinate the activities of the program. Other specific terms were not disclosed.
Find more details from the press release (a pdf file).
Comment Preview